Reham Dawood

Prof. Dr. Reham Dawood


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2019 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
RDReham Dawood
Reham Dawood
RMRehab I. Moustafa
Rehab I. Moustafa
TATawfeek H. Abdelhafez
Tawfeek H. Abdelhafez
REReem El-Shenawy
Reem El-Shenawy
YEYasmine El-Abd
Yasmine El-Abd
MAMostafa K. El Awady
Mostafa K. El Awady
Background: Although DAAs hold promise to significantly reduce rates of chronic HCV infections, its eradication still requires development of an effective vaccine. Prolonged T cell responses and cross neutralizing antibodies are ideal for vaccination against the infection. We aimed to design and synthesize a 6 multi epitope peptide vaccine candidate and provide evidence for production of extended cellular and neutralizing Abs in mice. Methods: Six peptides derived from conserved epitopes in E1, E2 (n = 2),NS4B, NS5A and NS5B were designed, synthesized in a multiple antigenic peptide (MAP) form and administered w/o adjuvant to BALB/c mice as HCVp6-MAP at doses ranging from 800 ng to 16 μg. Humoral responses to structural epitopes were assayed by ELISA at different times after injection. ELISpot assay was used to evaluate IFN ɣ producing CD4+/ CD8+ T- lymphocytes at extended durations i.e. > 20 weeks. Viral neutralization by mice sera was tested for genotypes 2a (JFH1) and a chimeric 2a/4a virus (ED43/JFH1) in HCVcc culture. Results: HCVp6-MAP confers potent viral neutralization and specific cellular responses at > 1600 ng/ animal for at least 20 weeks. Conclusion: We report on a promising anti HCV vaccine for future studies on permissive hosts and in clinical trials.

6 November 2021 in The American Journal of the Medical Sciences
Verified
Journal Article
Closed access
RDReham Dawood
Reham Dawood
GSGhada Maher Salum
Ghada Maher Salum
MEMai Abd El-Meguid
Mai Abd El-Meguid

1 September 2020 in Genes & Diseases
Verified
Journal Article
Open access
GSGhada Salum
Ghada Salum
RDReham Dawood
Reham Dawood
MEMai Abd El-Meguid
Mai Abd El-Meguid
NINoha E. Ibrahim
Noha E. Ibrahim
AAAshraf O. Abdel Aziz
Ashraf O. Abdel Aziz
MAMostafa K. El Awady
Mostafa K. El Awady
In Egypt, Sofosbuvir (SOF) in combination with Dataclasvir (DCV) is the broadly used DAAs with excellent therapeutic profile. This study is designed to explore the relation between IL28B/TLR4 genetic variants and each of the followings; HCC development post SOF/DCV treatment, progression to HCC in naïve patients and SOF/DCV therapy outcome. A total of 493 blood samples were collected (controls (n = 70); HCV patients treated with SOF/DCV (n = 252) of whom 65 patients developed HCC, 187 patients didn't develop HCC (125 responders, 62 relapsers); naïve HCV patients (n = 171) had early (n = 48), late liver fibrosis (n = 21) and HCC (n = 102)). Both SNPs were genotyped using a TaqMan 5′ allelic discrimination assay. At IL28B rs12979860 SNP, the C allele was significantly correlating with the response rate more than T allele (OR 1.9, 95% CI 1.29–2.9, p = 0.004), while at TLR4 rs4986791 SNP, no association was found (OR 6.5, 95% 0.57–75.28, p = 0.09). Both SNPs couldn't detect the probability for HCC emergence after treatment. In naïve patients, the protective alleles were detected in their lowest frequency in HCC patients (p = 0.1, for rs12979860 and, p = 0.001 for rs4986791). SOF/DCV combination improved SVR rates in HCV genotype 4a infected patients regardless of IL28B genotype, with the best rates in those lacking the T allele.

1 November 2015 in Viral Immunology
Verified
Journal Article
Closed access
NDNoha G. Bader El Din
Noha G. Bader El Din
MAMohamed Mohamed Anany
Mohamed Mohamed Anany
RDReham Dawood
Reham Dawood
MIMarwa K. Ibrahim
Marwa K. Ibrahim
REReem El-Shenawy
Reem El-Shenawy
MAMostafa El Awady
Mostafa El Awady
The aim of this study was to assess the impact of genetic variants of oligoadenylate synthetase 1 (OAS1) single-nucleotide polymorphism (SNP) rs10774671 at the exon 7 splice acceptor site on liver fibrosis progression and hepatitis C virus (HCV) outcome in Egyptian HCV genotype 4 patients. In this study, 195 subjects were enrolled; 60 controls and 135 chronic HCV genotype 4 patients with different fibrosis grades. All subjects were genotyped for OAS1 SNP rs10774671 polymorphism by polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) analysis. There was an increasing trend of liver fibrosis progression as 52.9% GG, 73.6% GA, and 83.3% AA genotypes were detected in late fibrosis patients (p = 0.025). The AA genotype was higher in the late fibrosis group than in the early fibrosis group (83.3% vs. 16.7%) (p = 0.001). The A allele was significantly affecting the liver fibrosis progression rate, more than the G allele (p = 0.001). The multivariate analysis showed that the OAS1 GA and AA genotypes were independent factors associated with liver progression (p = 0.009, odds ratio [OR] 3.467, 95% confidence interval [CI] 1.273–7.584). In addition, the A allele was associated with liver fibrosis progression (p = 0.014, OR 2.525, 95% CI 1.157–4.545). The polymorphism at OAS1 exon 7 rs3741981 might be a potential genetic marker and can be useful in the assessment of liver fibrosis progression and disease outcome in HCV-infected patients.

1 January 2017 in Biomarker Insights
Verified
Journal Article
Open access
NMNagwa A Meguid
Nagwa A Meguid
SGSaid A S Ghozlan
Said A S Ghozlan
MMMagda F Mohamed
Magda F Mohamed
MIMarwa K Ibrahim
Marwa K Ibrahim
RDReham Dawood
Reham Dawood
MAMostafa El Awady
Mostafa El Awady
The molecular basis of the pathophysiological role of oxidative stress in autism is understudied. Herein, we used polymerase chain reaction (PCR) array to analyze transcriptional pattern of 84 oxidative stress genes in peripheral blood mononuclear cell pools isolated from 32 autistic patients (16 mild/moderate and 16 severe) and 16 healthy subjects (each sample is a pool from 4 autistic patients or 4 controls). The PCR array data were further validated by quantitative real-time PCR in 80 autistic children (55 mild/moderate and 25 severe) and 60 healthy subjects. Our data revealed downregulation in GCLM, SOD2, NCF2, PRNP, and PTGS2 transcripts (1.5, 3.8, 1.2, 1.7, and 2.2, respectively;P < .05 for all) in autistic group compared with controls. In addition, TXN and FTH1 exhibited 1.4- and 1.7-fold downregulation, respectively, in severe autistic patients when compared with mild/moderate group (P = .005 and .0008, respectively). This study helps in a better understanding of the underlying biology and related genetic factors of autism, and most importantly, it presents suggested candidate biomarkers for diagnosis and prognosis purposes as well as targets for therapeutic intervention.

31 July 2013 in AIDS
Verified
Journal Article
Closed access
FBFahd Benjelloun
Fahd Benjelloun
RDReham Dawood
Reham Dawood
SUSilvio Urcuqui-Inchima
Silvio Urcuqui-Inchima
BCBlandine Chanut
Blandine Chanut
BVBernard Verrier
Bernard Verrier
SPStéphane Paul
Stéphane Paul
This preliminary study was performed to assess the neutralization activity of anti-MPER-secretory IgA (SIgA) from parotid saliva in 88 HIV+ patients, in five exposed seronegative (ESN) and in five seronegative volunteers. 48.9% of the HIV+ patients and 100% of ESN patients showed antigp41 SIgA. 25.6% of anti-MPER SIgA from HIV+ patients and 100% from ESN patients neutralized efficiently HIV-1 primary isolate SF162 (IC 50). The neutralization activity is maintained for much lower concentrations in ESN than in HIV+ secretions.